Skip to main content
. 2017 Dec 12;12:3549–3556. doi: 10.2147/COPD.S150827

Table 1.

Baseline characteristics of patients according to their medical equipment

Characteristics Total patients LTOT NIV CPAP NE
Sample size (n) 298 109 84 25 80
Men to women ratio (n) 199/99 73/36 56/28 20/5 50/30
Age (years) 63.8±11.0 64.8±11.8 64.9±8.8 64.9±11.9 60.7±11.2
BMI (kg/m2) 27.0±7.6 24.9±6.5b 29.4±9.0c 33.6±5.5c 25.6±6.3b
FEV1 (L) 1.117±0.536 0.930±0.423d 0.962±0.464d 1.409±0.575 1.380±0.563
FEV1 (% theoretical value) 40.9±17.1 35.0±14.9d 34.3±14.5d 53.0±16.1 49.9±16.1
FVC (% theoretical value) 66.2±20.1 59.9±19.8d 60.6±18.4a 74.7±16.6 75.8±18.5
FEV1/FVC 50.6±12.8 46.2±11.7d 48.6±12.4e 58.3±9.1 54.9±12.9
Moderate airflow limitation (50%≤FEV1<80%), n (%) 71 (23.8) 15 (13.8)d 10 (11.9)d 12 (48.0) 34 (42.5)
Severe airflow limitation (30%≤FEV1<50%), n (%) 132 (44.3) 48 (44.0) 35 (41.7) 11 (44.0) 38 (47.5)
Very severe airflow limitation (FEV1<30%), n (%) 95 (31.9) 46 (42.2)d 39 (46.4)d 2 (8.0) 8 (10.0)
TLC (% theoretical value) 108.9±26.3 106.8±31.5 112.8±25.1 102.3±17.0 109.1±24.4
Short-acting β2-agonists, n 160 69 47 7 37
Long-acting β2-agonists, n 120 50 30 5 35
Long-acting anticholinergic, n 193 80 65 9 39
Bronchodilator associated with corticosteroids, n 145 58 40 11 36
Inhaled corticosteroids, n 46 21 17 3 5
Oral corticosteroids, n 61 38 12 2 9

Notes: Data shown as n, mean ± standard deviation, or n (%).

a

Significantly different from NE (p<0.05).

b

Significantly different from CPAP and NIV (p<0.05).

c

Significantly different from all others groups (p<0.05).

d

Significantly different from CPAP and NE (p<0.05).

e

Significantly different from CPAP (p<0.05).

Abbreviations: BMI, body mass index; CPAP, continuous positive airway pressure; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; LTOT, long-term oxygen therapy; n, sample size; NE, no equipment; NIV, noninvasive ventilation; TLC, total lung capacity.